Marinus Pharmaceuticals Inc
NASDAQ:MRNS
Intrinsic Value
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. [ Read More ]
The intrinsic value of one
MRNS
stock under the Base Case scenario is
6.83
USD.
Compared to the current market price of 1.42 USD,
Marinus Pharmaceuticals Inc
is
Undervalued by 79%.
MRNS's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
MRNS or that its price is influenced by factors unrelated to fundamentals.
Marinus Pharmaceuticals Inc's market capitalization is 77.5m USD.
MRNS stock price is 1.42 USD.
MRNS stock price (1.42 USD) is 79% less than its Intrinsic Value (6.83 USD).
MRNS. Open DCF Valuation
MRNS has upside potential of 520% compared to the average analyst price target.
Open Wall St Estimates
MRNS's long-term assets (171m USD) exceed its long-term liabilties (154m USD).
MRNS's Revenue has grown by an exceptional 22% over the past 12 months.
MRNS's ROE (Return on Equity) has significantly decreased in the last 3 years from -81% to -213%, and is approaching profitability.
MRNS's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 657% to -839%, and is approaching profitability.
MRNS has negative Operating Income for the last twelve months.
MRNS has negative Net Income for the last twelve months.
MRNS's ROE (Return on Equity) for the past 12 months is negative and is equal to -213%.
MRNS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -839%.
MRNS has positive Gross Profit for the last twelve months.
MRNS has negative Net Debt. This means that the company has more cash and short-term investments (150m USD) than debt (61m USD).
MRNS's Revenue is forecast to grow at a rate of 73% per year over the next 3 years.
MRNS has negative Free Cash Flow for the last twelve months.
MRNS's Revenue has been growing by an exceptional 162% per year for the last 3 years.
MRNS's D/E (Debt to Equity) is very high and is equal to 3.66.
MRNS has negative three-year average ROE (Return on Equity): -106%. The company is not efficient at transforming stockholders' equity into net income.
MRNS has negative three-year average ROIC (Return on Invested Capital): -999%. The company is not efficient at using invested capital to generate operating income.
MRNS's short-term assets (165m USD) exceed its short-term liabilties (41m USD).
MRNS's Altman Z-Score is very low and is equal to -4.91.
MRNS doesn't generate enough operating income (-131m USD) to safely cover interest payments on its debt (9m USD).
Valuation Backtest
Marinus Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
MRNS
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Marinus Pharmaceuticals Inc
Balance Sheet Decomposition
Marinus Pharmaceuticals Inc
| Current Assets | 165.2m |
| Cash & Short-Term Investments | 150.3m |
| Receivables | 3.8m |
| Other Current Assets | 11.2m |
| Non-Current Assets | 5.7m |
| PP&E | 4.8m |
| Other Non-Current Assets | 819k |
| Current Liabilities | 40.6m |
| Accounts Payable | 4m |
| Accrued Liabilities | 22.9m |
| Other Current Liabilities | 13.8m |
| Non-Current Liabilities | 113.5m |
| Long-Term Debt | 61.4m |
| Other Non-Current Liabilities | 52.1m |
Earnings Waterfall
Marinus Pharmaceuticals Inc
|
Revenue
|
31m
USD
|
|
Cost of Revenue
|
-1.9m
USD
|
|
Gross Profit
|
29.1m
USD
|
|
Operating Expenses
|
-160.5m
USD
|
|
Operating Income
|
-131.5m
USD
|
|
Other Expenses
|
-9.9m
USD
|
|
Net Income
|
-141.4m
USD
|
Free Cash Flow Analysis
Marinus Pharmaceuticals Inc
MRNS Profitability Score
Profitability Due Diligence
Marinus Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Marinus Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
MRNS Solvency Score
Solvency Due Diligence
Marinus Pharmaceuticals Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Marinus Pharmaceuticals Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRNS Price Targets Summary
Marinus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
MRNS
is 8.8 USD
.
Ownership
MRNS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
MRNS Price
Marinus Pharmaceuticals Inc
| Average Annual Return | -18.3% |
| Standard Deviation of Annual Returns | 52.84% |
| Max Drawdown | -94% |
| Market Capitalization | 77.5m USD |
| Shares Outstanding | 54 931 000 |
| Percentage of Shares Shorted | 6.41% |
Company Profile
Marinus Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 113 full-time employees. The company went IPO on 2014-07-31. The firm is focused on the development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. The Company’s lead product candidate is ZTALMY (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), which is developed for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD). Ganaxolone is a methylated analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A (GABAA) receptors, a target known for its anti-seizure, antidepressant, and anxiolytic potential.
Contact
IPO
Employees
Officers
The intrinsic value of one
MRNS
stock under the Base Case scenario is
6.83
USD.
Compared to the current market price of 1.42 USD,
Marinus Pharmaceuticals Inc
is
Undervalued by 79%.
You don't have any saved screeners yet
